

ASX Announcement

Imugene appoints leading cancer researcher to Scientific Advisory Board

Sydney, Australia - 01 October 2018 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the appointment of Professor Pravin Kaumaya of Ohio State University Comprehensive Cancer Centre to its Scientific Advisory Board (SAB).

Imugene Managing Director and CEO Leslie Chong said, “Professor Kaumaya is an acknowledged leader in cancer vaccine research and will greatly enhance the insights Imugene receives from its scientific advisory board as we advance our expanded cancer immuno-therapy product pipeline.”

Prof Kaumaya is the lead inventor of Imugene’s newly licensed peptide cancer vaccine programs from Ohio State University. He has developed multiple cancer vaccines, is a recognised world leader in cancer vaccine research and author of more than 130 peer-reviewed articles.

He is Professor of Medicine in Department of Obstetrics and Gynecology at the Ohio State University Wexner Medical Center and the James Comprehensive Cancer Center.

Prof Kaumaya’s team and medical research laboratory at OSU is focused on a number of translational research programs with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment and prevention.

He is an inventor on several issued and pending patents for peptide vaccines and therapeutic technologies, an elected fellow of the American Association for the Advancement of Science (AAAS) and treasurer of the American Peptide Society.

Following the recent enhancements to the Scientific Advisory Board and the executive team, Prof. Urusla Wiedermann has retired as Imugene’s Chief Scientific Officer. Prof. Wiedermann has provided exceptional scientific guidance in her role as CSO and Imugene will continue to benefit from her scientific expertise as she continues to remain on the scientific advisory board.

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

Follow us on Twitter @ TeamImugene

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body's immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure Imugene and its shareholders are at the forefront of this rapidly growing global market.